logo

For the Inventor, By the Inventor

Bellbird Park, Australia

Stephen Maxwell Taylor

This inventor holds 8 USPTO granted patents and 4 published patent applications and 1 EPO patent. Top assignees: The University of Queensland, Promics Pty Limited, The Board of Regents of the University of Nebraska. Active years: 1997-2011.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Stephen Maxwell Taylor. Retrieved from https://idiyas.com/inventor/stephen-maxwell-taylor

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 8 

% Patents Active = 50.0

 

Average Co-Inventor Count = 3.9

ph-index = 4

Forward Citations = 46(Granted Patents)


Company Filing History:

goldMedal4 out of 345 
 
The University of Queensland
 patents
silverMedal3 out of 4 
 
Promics Pty Limited
 patents
bronzeMedal3 out of 969 
 
The Board of Regents of the University of Nebraska
 patents
where one patent can have more than one assignee

Years Active: 1997-2011

Loading Chart...
Loading Chart...
8 patents (USPTO):Explore Patents
1. 7919459 - Use of C5a receptor antagonist in the treatment of fibrosis (2011-04-05),
2. RE41287 - Cyclic agonists and antagonists of C5A receptors and G Protein-coupled receptors (2010-04-26),
3. 7579432 - Cyclic peptides as G-protein-coupled receptor antagonists (2009-08-25),
4. 7410945 - Treatment of inflammatory bowel disease (2008-08-12),
5. 6821950 - Cyclic agonists and antagonists of C5a receptors and G protein-coupled receptors (2004-11-23),
6. 6465614 - High-affinity response-selective C-terminal analogs of C5a anaphylatoxin (2002-10-15),
7. 5942599 - High-affinity response-selective C-terminal analogs of C5a anaphylatoxin (1999-08-24),
8. 5696230 - High-affinity response-selective C-terminal analogs of C5a anaphylatoxin (1997-12-09),

Title: Innovations and Contributions of Stephen Maxwell Taylor

Introduction

Stephen Maxwell Taylor is a notable inventor based in Bellbird Park, Australia. He has made significant contributions to the field of medical research, particularly in the treatment of fibrotic conditions. With a total of 8 patents to his name, Taylor's work has the potential to impact various therapeutic areas.

Latest Patents

One of his latest patents focuses on the use of a C5a receptor antagonist in the treatment of fibrosis. This invention relates to the use of an antagonist of a G protein-coupled receptor in the prevention and/or treatment of fibrosis, including conditions associated with myocardial infarction, diabetes, or certain pulmonary issues. The preferred embodiment of this invention involves a cyclic peptide antagonist of the C5a receptor. Additionally, he has developed cyclic agonists and antagonists of C5A receptors and G protein-coupled receptors, which are useful in treating conditions mediated by these receptors, particularly inflammatory conditions.

Career Highlights

Throughout his career, Stephen Maxwell Taylor has worked with prestigious institutions, including The University of Queensland and the University of Nebraska. His research has contributed to advancements in medical treatments and has garnered attention in the scientific community.

Collaborations

Taylor has collaborated with notable colleagues such as David P Fairlie and Sam D Sanderson. These partnerships have further enriched his research and innovation efforts.

Conclusion

Stephen Maxwell Taylor's contributions to the field of medical research through his patents and collaborations highlight his role as an influential inventor. His work continues to pave the way for advancements in the treatment of fibrotic and inflammatory conditions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…